T
Tetsuya Mitsudomi
Researcher at Kindai University
Publications - 583
Citations - 51959
Tetsuya Mitsudomi is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 97, co-authored 541 publications receiving 46183 citations. Previous affiliations of Tetsuya Mitsudomi include University of Occupational and Environmental Health Japan & Gunma University.
Papers
More filters
Journal ArticleDOI
Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
H Sakamoto,J Shimizu,Yoshitsugu Horio,Ryuzo Ueda,Takashi Takahashi,Tetsuya Mitsudomi,Yasushi Yatabe +6 more
TL;DR: It is suggested that AAH could develop by either KRAS or EGFR gene mutation, but AAH harbouring a KRAS gene mutation might not progress further to an invasive cancer.
Journal ArticleDOI
Epidermal growth factor receptor inhibition in lung cancer: Status 2012
Fred R. Hirsch,Pasi A. Jänne,Wilfried Eberhardt,Federico Cappuzzo,Nick Thatcher,Robert Pirker,Hak Choy,Edward S. Kim,Luis Paz-Ares,David R. Gandara,Yi-Long Wu,Myung-Ju Ahn,Tetsuya Mitsudomi,Frances A. Shepherd,Tony Mok +14 more
TL;DR: This review summarizes the current status of EGFR inhibitors in NSCLC in 2012 and some of the major challenges the authors are facing.
Journal ArticleDOI
Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
Myung-Ju Ahn,Chun-Ming Tsai,Frances A. Shepherd,Lyudmila Bazhenova,Lecia V. Sequist,Toyoaki Hida,James Chih-Hsin Yang,Suresh S. Ramalingam,Tetsuya Mitsudomi,Pasi A. Jänne,Helen Mann,Mireille Cantarini,Glenwood D. Goss +12 more
TL;DR: The authors present long‐term follow‐up data from a preplanned, pooled analysis of phase 2 studies, the AZD9291 First Time in Patients Ascending Dose Study (AURA) extension trial (clincialtrials.gov identifier NCT01802632) and the AURA2 trial (NCT02094261).
Journal ArticleDOI
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer
Kenji Suzuki,Shun-ichi Watanabe,Masashi Wakabayashi,Hisashi Saji,Keiju Aokage,Yasumitsu Moriya,Ichiro Yoshino,Masahiro Tsuboi,Shinichiro Nakamura,Kenichi Nakamura,Tetsuya Mitsudomi,Hisao Asamura +11 more
TL;DR: Sublobar resection with enough surgical margin offered sufficient local control and relapse-free survival for lung cancer clinically resectable N0 staged by computed tomography with 3 or fewer peripheral lesions.
Journal ArticleDOI
Surgical treatment of lung cancer in the octogenarian.
Toshihiro Osaki,Toshihiro Osaki,Takayuki Shirakusa,Takayuki Shirakusa,Mantaro Kodate,Mantaro Kodate,Ryoichi Nakanishi,Ryoichi Nakanishi,Tetsuya Mitsudomi,Tetsuya Mitsudomi,Hitoshi Ueda,Hitoshi Ueda +11 more
TL;DR: The data suggest that the octogenarian who suffers from lung cancer deserves the opportunity for a cure and the long-term benefits of surgical treatment, on the condition that no postoperative major cardiorespiratory complications set in.